The combination of daclatasvir, a hepatitis C virus (HCV) NS5A inhibitor, and the NS5B inhibitor sofosbuvir has shown efficacy in patients with HCV monoinfection. Data are lacking on the efficacy and safety of this combination in patients coinfected with human immunodeficiency virus type 1 (HIV-1).
Original Source [2]
Technology Partners: MimirTech
Links:
[1] http://admin.indiaenvironmentportal.org.in/feature-article/daclatasvir-plus-sofosbuvir-hcv-patients-coinfected-hiv-1
[2] http://www.nejm.org/doi/pdf/10.1056/NEJMoa1503153
[3] http://admin.indiaenvironmentportal.org.in/category/author/dl-wyles
[4] http://admin.indiaenvironmentportal.org.in/category/author/pj-ruane
[5] http://admin.indiaenvironmentportal.org.in/category/author/ms-sulkowski-et-al
[6] http://admin.indiaenvironmentportal.org.in/category/journal/new-england-journal-medicine
[7] http://admin.indiaenvironmentportal.org.in/category/thesaurus/aids
[8] http://admin.indiaenvironmentportal.org.in/category/thesaurus/hepatitis
[9] http://admin.indiaenvironmentportal.org.in/category/thesaurus/drugs
[10] http://admin.indiaenvironmentportal.org.in/category/thesaurus/medical-research
[11] http://admin.indiaenvironmentportal.org.in/category/thesaurus/united-states-america-us
